Alameda Health System (AHS) implemented a large-scale colorectal cancer screening outreach initiative using the Cologuard, at-home test to enhance access to screenings. This effort was in partnership with Alameda Alliance and Exact Sciences.
“We sent out screening kits to over 3,000 patients who were overdue, surpassing any previous bulk screening efforts we’ve done so far at AHS,” said Natalie Curtis, MD, medical director of ambulatory health outcomes. “Approximately 18% completed the screening test and at least one case of colon cancer was diagnosed through the outreach campaign.”
This expanded screening effort is crucial because detecting colorectal cancer in its early stages significantly improves treatment outcomes. “Screening tests allow us to find asymptomatic precancer and cancer,” said Dr. Curtis “Finding precancerous polyps allows us to decrease rates of colon cancer diagnosed.”
CRC is the fourth most common cancer in the U.S. among men and women combined, yet it is also one of the most preventable. It ranks as the second leading cause of cancer-related deaths, but when caught early through routine screenings, it is highly treatable. Dr. Curtis shared that unlike the fecal immunochemical test (FIT), which requires annual testing, Cologuard results are valid for up to three years.
“Early detection is critical because colorectal cancer can often develop without noticeable symptoms until it reaches a later stage,” said Dr. Curtis. “That’s why routine screening is so important. It can improve outcomes and ultimately save lives.”
Another strategy to boost screening rates includes partnering with the AHS Health Outcomes Outreach Team (HOOT) who call patients that haven’t completed their tests, offering reminders, support and answers to questions. Patients also receive MyChart notifications or text messages if they’re not on MyChart.
While early detection is crucial for everyone, the impact of delayed screenings and treatment is especially severe in Black communities, where colorectal cancer outcomes are significantly worse.
Black Americans face a disproportionate burden from colorectal cancer. The Centers for Disease Control and Prevention (CDC) share that Black patients are about 20% more likely to be diagnosed with colorectal cancer and 40% more likely to die from it compared to their white counterparts.
The CDC points to systemic barriers to health care, lower screening rates, and disparities in access to high-quality treatment which contribute to these inequities. “By increasing screenings and educating at-risk communities, we can take meaningful steps toward equity in care,” shared Dr. Curtis.
Regular colorectal cancer screening is recommended for those who are 45 or older. Options include a colonoscopy every 10 years or a stool test every 1-3 years. Discuss with your doctor to determine the best screening option.
March is Colorectal Cancer Awareness Month, a time to highlight the importance of early detection, prevention and equitable access to screenings. Visit our Get Screened for Life website for more information including how AHS patients can schedule a screening.